12 November 2012
Moscow, November 12, 2012 – Fabrice Egros was appointed as COO, Pharmaceutical Director and board member of NovaMedica, a novel Russian pharmaceutical company, which was established within the frameworks of the joint project between RUSNANO and the American venture fund Domain Associates.
The partnership involves joint investment in advanced medical technologies and late stage innovative drugs for their development, manufacture and commercialization, including the creation of a GMP production facility in Russia.
Mr. Egros has more than 20 years of international experience of work in the pharmaceutical industry. Prior to coming to NovaMedica he held managerial positions at Xanodyne, UCB (in Belgium, the USA and Japan). Fabrice also worked in others pharmaceutical companies, as Parke-Davis/Warner Lambert in Germany and the USA, Sanofi-Aventis in Japan and the USA. His responsibilities have encompassed Clinical development , marketing , market access , sales , Business development and general management functions Fabrice received his Pharm D and Ph.D in pharmaceutical sciences degrees at Chatenay Malabry University (Paris, France), a diploma in business administration from Schiller International University (Dunedin, Florida, USA). Besides that he studied Advanced Management Program at Harvard University (Cambridge, Massachusetts, USA).
“We have set ourselves the non-negotiable objective of building a Russian company that will be driven and inspired by the very best of international best practice in all facets of its operations and values - from day one. We also have ambitious and far-reaching plans to pursue joint business development activities with the most innovative Western players in the pharmaceuticals and life sciences space. For both of these reasons I am delighted that we have Fabrice Egros on board as our COO – he is a highly experienced life sciences senior executive with successful exposure to pharma markets across the globe” said Leonid Melamed, NovaMedica CEO.
“Now I see my top priority in the creation of a great team of globally experienced life sciences industry talents from R&D, CMC, regulatory, business development , marketing and sales, to create the next generation life science company in Russia" - said F.Egros.
RUSNANO was established in March 2011 as an open joint stock company through the reorganization of the state corporation Russian Corporation of Nanotechnologies. RUSNANO's mission is to develop the Russian nanotechnology industry through co-investment in nanotechnology projects with substantial economic potential or social benefit. The Government of the Russian Federation owns 100 percent of the shares in RUSNANO. Work to establish a nanotechnology infrastructure and training for nanotechnology specialists, formerly conducted by the Russian Corporation of Nanotechnologies, has been entrusted to the Fund for Infrastructure and Educational Programs, a non-commercial fund also established through the reorganization of the Russian Corporation of Nanotechnologies.
About Domain Associates
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2.4 billion of capital under management, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA. Domain’s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices, while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics. The Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 235 life-sciences companies. The highly focused network, experience, and reputation of this team have made it one of the top private-equity groups participating in the healthcare field.
19 October 2018
18 October 2018
18 October 2018
17 October 2018